Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novartis formed Dec. 20 following FTC approval of Sandoz/Ciba merger.

This article was originally published in The Tan Sheet

Executive Summary

NOVARTIS AG ESTABLISHED DEC. 20 FOLLOWING FTC PROVISIONAL APPROVAL of the merger between Sandoz and Ciba-Geigy, the companies announced. The two firms reported their intention to merge on March 7 ("The Tan Sheet" March 11, p. 1). Novartis shares will begin trading on the Swiss stock exchange Dec. 23. The Federal Trade Commission's Dec. 17 provisional approval of the merger came nearly six months after the European Commission signed off on the agreement ("The Tan Sheet" July 22, In Brief).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS086489

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel